StemCell Therapy

March 21, 2017 Credit: University of Bristol

Researchers have shown stem cells from the umbilical cord may hold the key to a new generation of graft and could reduce the number of surgeries required to treat young children born with certain types of congenital heart disease.

Congenital heart disease (CHD) is the most common type of birth defect. In the UK alone over 4,000 babies are diagnosed with CHD each year and thanks to advances in treatment and care, more than eight out of ten CHD babies grow up to be adults.

However, the only treatment for these conditions is corrective surgery where a piece of tissue, known as an implant, is used to replace the damaged area. Often surgery has to be repeated several times throughout childhood as the child's heart outgrows the artificial implant used to repair it.

Professors Massimo Caputo and Paolo Madeddu, in the Bristol Heart Institute, a newly created specialist research institute (SRI) at the University of Bristol, have developed cellular grafts using stem cells from the umbilical cord and placenta that are able to grow like living tissue and it is hoped would be able to grow along with a child's heart. These new grafts would mean that instead of having multiple operations to insert bigger grafts as the patient's heart grows only one operation would be needed.

These grafts have been tested in animal models that closely resemble the 'real-world' scenario and tested for their capacity to grow and regenerate the damaged heart. The researchers are also exploring which cells are best suited for the graft so that a wide range of treatment options and solutions could be tailored to the patients' needs. With the first two phases of research completed, the academics are now preparing to start a clinical trial in newborn babies.

Massimo Captuo, Professor of Congenital Heart Surgery from the School of Clinical Sciences, said: "We believe stem cells from the umbilical cord, usually discarded after birth, could hold the key to a new generation of graft. These grafts grow at the same rate as the children they're used to treat and reduce the risk of rejection after transplant as they contain the child's own DNA."

Paolo Madeddu, Professor of Experimental Cardiovascular Medicine from the School of Clinical Sciences, added: "The long-term outcomes for most young children remains poor and significantly affects their quality of life. By developing these new grafts, we hope to reduce the amount of surgeries that a child born with congenital heart disease must go through."

Explore further: Engineered blood vessels grow in lambs

In a hopeful development for children born with congenital heart defects, scientists said Tuesday they had built artificial blood vessels which grew unaided when implanted into lambs, right into adulthood.

Current cardiovascular valve or blood vessel implants are generally associated with a number of complications, have limited efficacy over time, and may necessitate repeated interventions over a patient's lifetime, especially ...

Mayo Clinic has announced the first U.S. stem cell clinical trial for pediatric congenital heart disease. The trial aims to determine how stem cells from autologous umbilical cord blood can help children with hypoplastic ...

In a first-in-children randomized clinical study, medical researchers at the University of Maryland School of Medicine (UM SOM) and the Interdisciplinary Stem Cell Institute (ISCI) at the University of Miami Miller School ...

Over one million children are born with congenital heart disease (CHD) each year. When children with CHD receive timely treatment, 85% can survive into adulthood to live healthy, productive lives. Sadly, 90% of the children ...

A new minimally invasive technique for repairing the most common cardiac birth defect in extremely premature newborns can be performed safely with a high success rate in babies as small as 755 grams - about 1.6 pounds - only ...

A small protein that could protect the brain from stroke-induced injury has been discovered by researchers from The University of Queensland and Monash University.

ATMs and coffee shops such as Tim Hortons, Starbucks and Second Cup make ideal locations for placing automated external defibrillators (AEDs), according to a new study led by U of T Engineering researchers Professor Timothy ...

About 12 percent of patients undergoing aortic valve replacement developed non-symptomatic blood clots around the valve leaflets (known as subclinical leaflet thrombosis) that reduced the motion of the valves, according to ...

Substituting rivaroxaban for aspirin in patients with acute coronary syndromes (ACS) appears to cause no significant increase in bleeding risk, according to a study led by scientists from the Duke Clinical Research Institute ...

People who received regular lifestyle counseling online were able to lower their blood pressure as much as a medication would, researchers said Saturday.

An international research team with prominent Canadian leadership has found that the blood thinner rivaroxaban is as safe as aspirin, and more effective at preventing recurrence of life-threatening blood clots in the legs ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

View post:
Stem cell therapy could help mend the youngest of broken hearts - Medical Xpress

This entry was posted on March 22, 2017 at 5:40 pm and is filed under Stem Cell Therapy. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |